Charles River Laboratories | CRL - Cash And Equivalent


Charles River Laboratories reported $213.77M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Agilent USD 1.76B 31M Dec/2025
Align Technology USD 1B 103.43M Sep/2025
Bio-Rad Laboratories USD 529.8M 134M Dec/2025
Bruker USD 293.1M 201.1M Sep/2025
Cardinal Health USD 2.78B 1.82B Dec/2025
Charles River Laboratories USD 213.77M 6.67M Dec/2025
Cigna USD 6.02B 1.7B Sep/2025
Concord Medical Services Hldg CNY 243.38M 85.1M Jun/2023
CVS Health USD 8.45B 645M Dec/2025
Danaher USD 4.62B 3.09B Dec/2025
Dentsply International USD 363M 4M Sep/2025
Elevance Health USD 9.49B 778M Dec/2025
Galapagos EUR 64.46M 43.61M Sep/2025
Hologic USD 2.17B 208.5M Dec/2025
Humana USD 4.2B 1.19B Dec/2025
Illumina USD 1.42B 368M Dec/2025
Incyte USD 3.58B 650.78M Dec/2025
Intrexon USD 9.34M 1.77M Jun/2024
IQVIA Holdings USD 1.98B 166M Dec/2025
Laboratory Of America USD 532.3M 65.8M Dec/2025
Lonza CHF 1.11B 286M Dec/2024
McKesson USD 2.96B 1.05B Dec/2025
Merck EUR 1.17B 161M Jun/2025
Mettler Toledo International USD 69.06M 7.24M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Quest Diagnostics USD 420M 12M Dec/2025
Revvity USD 919.86M 11.53M Dec/2025
Thermo Fisher Scientific USD 9.85B 7.87B Dec/2025
United Therapeutics USD 1.56B 217M Dec/2025
UnitedHealth USD 28.12B 2.49B Dec/2025
Veradigm USD 492.6M 7.57M Sep/2022
Waters USD 587.83M 128.71M Dec/2025
West Pharmaceutical Services USD 791.3M 162.8M Dec/2025